Mirtazapine, and mirtazapine-like compounds as possible pharmacotherapy for substance abuse disorders: Evidence from the bench and the bedside

Pharmacology and Therapeutics

Volumn 136, Issue 3, 2012, Pages 343-353

  Graves, Steven M ^a   Rafeyan, Roueen ^a,b   Watts, Jeffrey ^a,c   Napier, T Celeste ^a  

^a RUSH UNIVERSITY   (United States)

^b Resurrection Behavioral Health   (United States)

^c UNIVERSITY OF ILLINOIS   (United States)

Author keywords

Atypical antidepressant; Cue reactivity; Methamphetamine; Methamphetamine seeking; Self administration; Serotonin

Indexed keywords

ALPHA 2A ADRENERGIC RECEPTOR; AMFEBUTAMONE; ANTIRETROVIRUS AGENT; BUPRENORPHINE; CITALOPRAM; COCAINE; CYTOCHROME P450 1A2; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; FLUOXETINE; METHADONE; MIRTAZAPINE; MODAFINIL; NALTREXONE; NORTRIPTYLINE; OPIATE; PLACEBO; SEROTONIN 2A RECEPTOR; SEROTONIN 2C RECEPTOR; SEROTONIN 3 RECEPTOR; SERTRALINE; THIORIDAZINE;

ABSTINENCE; ALCOHOL ABUSE; ANXIETY DISORDER; BEDTIME DOSAGE; CANNABIS ADDICTION; CARDIOVASCULAR SYMPTOM; COCAINE DEPENDENCE; DEPRESSION; DOPAMINERGIC TRANSMISSION; DRUG CLEARANCE; DRUG DETOXIFICATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG SEEKING BEHAVIOR; DRUG SELF ADMINISTRATION; DRUG WITHDRAWAL; GENERALIZED ANXIETY DISORDER; HUMAN; INSTRUMENTAL CONDITIONING; MAJOR DEPRESSION; MEDICAL HISTORY; METHAMPHETAMINE DEPENDENCE; MOOD DISORDER; MORNING DOSAGE; NEUROTRANSMISSION; NONHUMAN; OPIATE ADDICTION; OPIATE SUBSTITUTION TREATMENT; PLACE PREFERENCE; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; REVIEW; SEDATION; SENSITIZATION; SIDE EFFECT; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; SUBSTANCE ABUSE; WITHDRAWAL SYNDROME;

ANIMALS; ANTIDEPRESSIVE AGENTS, TRICYCLIC; CENTRAL NERVOUS SYSTEM STIMULANTS; CONDITIONING (PSYCHOLOGY); HUMANS; METHAMPHETAMINE; MIANSERIN; RECEPTORS, SEROTONIN; SUBSTANCE-RELATED DISORDERS;

EID: 84867851889     PISSN: 01637258     EISSN: 1879016X     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2012.08.013     Document Type: Review

References (128)

1. M. Afshar, C.M. Knapp, O. Sarid-Segal, E. Devine, L.S. Colaneri, and L. Tozier The efficacy of mirtazapine in the treatment of cocaine dependence with comorbid depression Am J Drug Alcohol Abuse 38 2012 181 186
2. K.D. Alex, G.J. Yavanian, H.G. McFarlane, C.P. Pluto, and E.A. Pehek Modulation of dopamine release by striatal 5-HT2C receptors Synapse 55 2005 242 251
3. A.E. Altintoprak, N. Zorlu, H. Coskunol, F. Akdeniz, and G. Kitapcioglu Effectiveness and tolerability of mirtazapine and amitriptyline in alcoholic patients with co-morbid depressive disorder: a randomized, double-blind study Hum Psychopharmacol 23 2008 313 319
4. A. Barbon, C. Orlandi, V.L. La, L. Caracciolo, D. Tardito, and L. Musazzi Antidepressant treatments change 5-HT2C receptor mRNA expression in rat prefrontal/frontal cortex and hippocampus Neuropsychobiology 63 2011 160 168
5. A. Bechara Decision making, impulse control and loss of willpower to resist drugs: a neurocognitive perspective Nat Neurosci 8 2005 1458 1463
6. H.H. Berendsen, and C.L. Broekkamp Indirect in vivo 5-HT1A-agonistic effects of the new antidepressant mirtazapine Psychopharmacology 133 1997 275 282
7. M. Berk, C.S. Gama, S. Sundram, H. Hustig, L. Koopowitz, and R. D'Souza Mirtazapine add-on therapy in the treatment of schizophrenia with atypical antipsychotics: a double-blind, randomised, placebo-controlled clinical trial Hum Psychopharmacol 24 2009 233 238
8. K.S. Bhatia, S.T. Szabo, J.C. Fowler, W.C. Wetsel, and T.H. Lee Reversal of long-term methamphetamine sensitization by combination of pergolide with ondansetron or ketanserin, but not mirtazapine Behav Brain Res 223 2011 227 232
9. W.K. Bickel, and L.A. Marsch Toward a behavioral economic understanding of drug dependence: delay discounting processes Addiction 96 2001 73 86
10. W.K. Bickel, M.L. Miller, R. Yi, B.P. Kowal, D.M. Lindquist, and J.A. Pitcock Behavioral and neuroeconomics of drug addiction: competing neural systems and temporal discounting processes Drug Alcohol Depend 90 Suppl. 1 2007 S85 S91
11. W.K. Bickel, A.L. Odum, and G.J. Madden Impulsivity and cigarette smoking: delay discounting in current, never, and ex-smokers Psychopharmacology 146 1999 447 454
12. W.K. Bickel, J.A. Pitcock, R. Yi, and E.J. Angtuaco Congruence of BOLD response across intertemporal choice conditions: fictive and real money gains and losses J Neurosci 29 2009 8839 8846
13. M.R. Blum, S.H. Liao, S.S. Good, and de MP Pharmacokinetics and bioavailability of zidovudine in humans Am J Med 85 1988 189 194
14. A. Borkowska, W. Drozdz, M. Ziolkowska-Kochan, and J. Rybakowski Enhancing effect of mirtazapine on cognitive functions associated with prefrontal cortex in patients with recurrent depression Neuropsychopharmacol Hung 9 2007 131 136
15. S.C. Bowden, F.T. Crews, M.E. Bates, W. Fals-Stewart, and M.L. Ambrose Neurotoxicity and neurocognitive impairments with alcohol and drug-use disorders: potential roles in addiction and recovery Alcohol Clin Exp Res 25 2001 317 321
16. M.L. Brecht, von MC, and M.D. Anglin Predictors of relapse after treatment for methamphetamine use J Psychoactive Drugs 32 2000 211 220
17. M.J. Bubar, and K.A. Cunningham Serotonin 5-HT2A and 5-HT2C receptors as potential targets for modulation of psychostimulant use and dependence Curr Top Med Chem 6 2006 1971 1985
18. M.J. Bubar, and K.A. Cunningham Distribution of serotonin 5-HT2C receptors in the ventral tegmental area Neuroscience 146 2007 286 297
19. M.J. Bubar, and K.A. Cunningham Prospects for serotonin 5-HT2R pharmacotherapy in psychostimulant abuse Prog Brain Res 172 2008 319 346
20. M.J. Bubar, S.J. Stutz, and K.A. Cunningham 5-HT(2C) receptors localize to dopamine and GABA neurons in the rat mesoaccumbens pathway PLoS One 6 2011 e20508
21. B. Chanrion, C.C. Mannoury la, S. Gavarini, M. Seimandi, L. Vincent, and J.F. Pujol Inverse agonist and neutral antagonist actions of antidepressants at recombinant and native 5-hydroxytryptamine2C receptors: differential modulation of cell surface expression and signal transduction Mol Pharmacol 73 2008 748 757
22. A.R. Childress, P.D. Mozley, W. McElgin, J. Fitzgerald, M. Reivich, and C.P. O'Brien Limbic activation during cue-induced cocaine craving Am J Psychiatry 156 1999 11 18
23. S.J. Cho, K. Yook, B. Kim, T.K. Choi, K.S. Lee, and Y.W. Kim Mirtazapine augmentation enhances cognitive and reduces negative symptoms in schizophrenia patients treated with risperidone: a randomized controlled trial Prog Neuropsychopharmacol Biol Psychiatry 35 2011 208 211
24. G.N. Colfax, G.M. Santos, M. Das, D.M. Santos, T. Matheson, and J. Gasper Mirtazapine to reduce methamphetamine use: a randomized controlled trial Arch Gen Psychiatry 68 2011 1168 1175
25. W.M. Compton, and N.D. Volkow Abuse of prescription drugs and the risk of addiction Drug Alcohol Depend 83 Suppl. 1:S4-7 2008
26. C.C. Cruickshank, M.E. Montebello, K.R. Dyer, A. Quigley, J. Blaszczyk, and S. Tomkins A placebo-controlled trial of mirtazapine for the management of methamphetamine withdrawal Drug Alcohol Rev 27 2008 326 333
27. C. Davidson, R. Gopalan, C. Ahn, Q. Chen, P. Mannelli, and A.A. Patkar Reduction in methamphetamine induced sensitization and reinstatement after combined pergolide plus ondansetron treatment during withdrawal Eur J Pharmacol 565 2007 113 118
28. 2 receptor antagonists given in the acute withdrawal from daily cocaine injections can reverse established sensitization Eur J Pharmacol 453 2002 255 263
29. C. Davidson, T.H. Lee, Z. Xiong, and E.H. Ellinwood Ondansetron given in the acute withdrawal from a repeated cocaine sensitization dosing regimen reverses the expression of sensitization and inhibits self-administration Neuropsychopharmacology 27 2002 542 553
30. T.H. de Boer The pharmacologic profile of mirtazapine J Clin Psychiatry 57 Suppl. 4 1996 19 25
31. T.H. de Boer, G. Maura, M. Raiteri, C.J. de Vos, J. Wieringa, and R.M. Pinder Neurochemical and autonomic pharmacological profiles of the 6-aza- analogue of mianserin, Org 3770 and its enantiomers Neuropharmacology 27 1988 399 408
32. T.H. de Boer, F. Nefkens, A. van Helvoirt, and A.M. Van Delft Differences in modulation of noradrenergic and serotonergic transmission by the alpha-2 adrenoceptor antagonists, mirtazapine, mianserin and idazoxan J Pharmacol Exp Ther 277 1996 852 860
33. P. De Deurwaerdere, S. Navailles, K.A. Berg, W.P. Clarke, and U. Spampinato Constitutive activity of the serotonin2C receptor inhibits in vivo dopamine release in the rat striatum and nucleus accumbens J Neurosci 24 2004 3235 3241
34. P. De Deurwaerdere, and U. Spampinato Role of serotonin(2A) and serotonin(2B/2C) receptor subtypes in the control of accumbal and striatal dopamine release elicited in vivo by dorsal raphe nucleus electrical stimulation J Neurochem 73 1999 1033 1042
35. C.R. Delle, M. Salviati, S. Fiorentini, and M. Biondi Add-on mirtazapine enhances effects on cognition in schizophrenic patients under stabilized treatment with clozapine Exp Clin Psychopharmacol 15 2007 563 568
36. P. Devoto, G. Flore, L. Pira, G. Longu, and G.L. Gessa Mirtazapine-induced corelease of dopamine and noradrenaline from noradrenergic neurons in the medial prefrontal and occipital cortex Eur J Pharmacol 487 2004 105 111
37. V. Di Matteo, G. Di Giovanni, M. Di Mascio, and E. Esposito SB 242084, a selective serotonin2C receptor antagonist, increases dopaminergic transmission in the mesolimbic system Neuropharmacology 38 1999 1195 1205
38. S. Dracheva, B. Chin, and V. Haroutunian Altered serotonin 2C receptor RNA splicing in suicide: association with editing Neuroreport 19 2008 379 382
39. S. Dracheva, N. Patel, D.A. Woo, S.M. Marcus, L.J. Siever, and V. Haroutunian Increased serotonin 2C receptor mRNA editing: a possible risk factor for suicide Mol Psychiatry 13 2008 1001 1010
40. B. Eiermann, G. Engel, I. Johansson, U.M. Zanger, and L. Bertilsson The involvement of CYP1A2 and CYP3A4 in the metabolism of clozapine Br J Clin Pharmacol 44 1997 439 446
41. M.T. Englander, S.C. Dulawa, P. Bhansali, and C. Schmauss How stress and fluoxetine modulate serotonin 2C receptor pre-mRNA editing J Neurosci 25 2005 648 651
42. M. Filip Role of serotonin (5-HT)2 receptors in cocaine self-administration and seeking behavior in rats Pharmacol Rep 57 2005 35 46
43. M. Filip, M.J. Bubar, and K.A. Cunningham Contribution of serotonin (5-hydroxytryptamine; 5-HT) 5-HT2 receptor subtypes to the hyperlocomotor effects of cocaine: acute and chronic pharmacological analyses J Pharmacol Exp Ther 310 2004 1246 1254
44. M. Filip, M.J. Bubar, and K.A. Cunningham Contribution of serotonin (5-HT) 5-HT2 receptor subtypes to the discriminative stimulus effects of cocaine in rats Psychopharmacology 183 2006 482 489
45. M. Filip, and K.A. Cunningham Serotonin 5-HT(2C) receptors in nucleus accumbens regulate expression of the hyperlocomotive and discriminative stimulus effects of cocaine Pharmacol Biochem Behav 71 2002 745 756
46. P.J. Fletcher, A.J. Grottick, and G.A. Higgins Differential effects of the 5-HT(2A) receptor antagonost M100,907 and the 5-HT(2C) receptor antagonist SB242,084 on cocaine-iduced locomotor activity, cocaine self-administration and cocaine-induced reinstatement of responding Neuropschopharmacology 27 2002 576 586
47. P.J. Fletcher, Z. Rizos, J. Sinyard, M. Tampakeras, and G.A. Higgins The 5-HT2C receptor agonist Ro60-0175 reduces cocaine self-administration and reinstatement induced by the stressor yohimbine, and contextual cues Neuropsychopharmacology 33 2008 1402 1412
48. P.J. Fletcher, J. Sinyard, and G.A. Higgins The effects of the 5-HT(2C) receptor antagonist SB242084 on locomotor activity induced by selective, or mixed, indirect serotonergic and dopaminergic agonists Psychopharmacology 187 2006 515 525
49. A. Gobert, J.M. Rivet, F. Lejeune, A. Newman-Tancredi, A. dhumeau-Auclair, and J.P. Nicolas Serotonin(2C) receptors tonically suppress the activity of mesocortical dopaminergic and adrenergic, but not serotonergic, pathways: a combined dialysis and electrophysiological analysis in the rat Synapse 36 2000 205 221
50. R.Z. Goldstein, and N.D. Volkow Dysfunction of the prefrontal cortex in addiction: neuroimaging findings and clinical implications Nat Rev Neurosci 12 2011 652 669
51. S. Grant, E.D. London, D.B. Newlin, V.L. Villemagne, X. Liu, and C. Contoreggi Activation of memory circuits during cue-elicited cocaine craving Proc Natl Acad Sci U S A 93 1996 12040 12045
52. S.M. Graves, and T.C. Napier Mirtazapine alters cue-associated methamphetamine seeking in rats Biol Psychiatry 69 2011 275 281
53. S.M. Graves, and T.C. Napier SB 206553, a putative 5-HT2C inverse agonist, attenuates methamphetamine-seeking in rats BMC Neurosci 13 2012 65
54. S.M. Graves, A.L. Persons, J.L. Riddle, and N.T. Celeste The atypical antidepressant mirtazapine attenuates expression of morphine-induced place preference and motor sensitization Brain Res 1472 2012 45 53
55. A.J. Grottick, P.J. Fletcher, and G.A. Higgins Studies to investigate the role of 5-HT(2C) receptors on cocaine- and food-maintained behavior J Pharmacol Exp Ther 295 2000 1183 1191
56. I. Gurevich, H. Tamir, V. Arango, A.J. Dwork, J.J. Mann, and C. Schmauss Altered editing of serotonin 2C receptor pre-mRNA in the prefrontal cortex of depressed suicide victims Neuron 34 2002 349 356
57. N. Haddjeri, P. Blier, and C. De Montigny Acute and long-term actions of the antidepressant drug mirtazapine on central 5-HT neurotransmission J Affect Disord 51 1998 255 266
58. A.A. Herrold, F. Shen, M.P. Graham, L.K. Harper, S.E. Specio, and C.E. Tedford Mirtazapine treatment after conditioning with methamphetamine alters subsequent expression of place preference Drug Alcohol Depend 99 2009 231 239
59. D. Hoyer Functional correlates of serotonin 5-HT1 recognition sites 1988 59 71
60. L.D. Johnston, P.M. O'Malley, J.G. Bachman, and J.E. Schulenberg Monitoring the Future national survey results on drug use, 1975-2009 NIH Publication No 10-7584 vol. I 2010 [Secondary school students]
61. D. Jovanovski, S. Erb, and K.K. Zakzanis Neurocognitive deficits in cocaine users: a quantitative review of the evidence J Clin Exp Neuropsychol 27 2005 189 204
62. N. Kakui, F. Yokoyama, M. Yamauchi, K. Kitamura, T. Imanishi, and T. Inoue Anxiolytic-like profile of mirtazapine in rat conditioned fear stress model: Functional significance of 5-hydroxytryptamine 1A receptor and alpha1-adrenergic receptor Pharmacol Biochem Behav 92 2009 393 398
63. P.W. Kalivas, and N.D. Volkow The neural basis of addiction: a pathology of motivation and choice Am J Psychiatry 162 2005 1403 1413
64. L. Kang, D. Wang, B. Li, M. Hu, P. Zhang, and J. Li Mirtazapine, a noradrenergic and specific serotonergic antidepressant, attenuates morphine dependence and withdrawal in Sprague-Dawley rats Am J Drug Alcohol Abuse 34 2008 541 552
65. J. Kelder, C. Funke, T. De Boer, L. Delbressine, D. Leysen, and V. Nickolson A comparison of the physicochemical and biological properties of mirtazapine and mianserin J Pharm Pharmacol 49 1997 403 411
66. G.R. King, Z.P. Xiong, S. Douglass, and E.H. Ellinwood Jr. Long-term blockade of the expression of cocaine sensitization by ondansetron, a 5-HT3 receptor antagonist Eur J Pharmacol 394 2000 97 101
67. G.F. Koob, and N.D. Volkow Neurocircuitry of addiction Neuropsychopharmacology 35 2010 217 238
68. A.R. Kooyman, R. Zwart, P.M. Vanderheijden, J.A. Van Hooft, and H.P. Vijverberg Interaction between enantiomers of mianserin and ORG3770 at 5-HT3 receptors in cultured mouse neuroblastoma cells Neuropharmacology 33 1994 501 507
69. S. Kourrich, and M.J. Thomas Similar neurons, opposite adaptations: psychostimulant experience differentially alters firing properties in accumbens core versus shell J Neurosci 29 2009 12275 12283
70. G.N. Kumar, A.D. Rodrigues, A.M. Buko, and J.F. Denissen Cytochrome P450-mediated metabolism of the HIV-1 protease inhibitor ritonavir (ABT-538) in human liver microsomes J Pharmacol Exp Ther 277 1996 423 431
71. M. Labasque, J. Meffre, G. Carrat, C. Becamel, J. Bockaert, and P. Marin Constitutive activity of serotonin2C receptors at g protein-independent signaling: Modulation by RNA editing and antidepressants Mol Pharmacol 78 2010 818 826
72. G.M. Leggio, A. Cathala, M. Neny, F. Rouge-Pont, F. Drago, and P.V. Piazza In vivo evidence that constitutive activity of serotonin(2C) receptors in the medial prefrontal cortex participates in the control of dopamine release in the rat nucleus accumbens: Differential effects of inverse agonist versus antagonist J Neurochem 111 2009 614 623
73. J. Liappas, T. Paparrigopoulos, P. Malitas, E. Tzavellas, and G. Christodoulou Mirtazapine improves alcohol detoxification J Psychopharmacol 18 2004 88 93
74. J. Liappas, T. Paparrigopoulos, E. Tzavellas, and A. Rabavilas Mirtazapine and venlafaxine in the management of collateral psychopathology during alcohol detoxification Prog Neuropsychopharmacol Biol Psychiatry 29 2005 55 60
75. M.S. Lima, A.A. Reisser, B.G. Soares, and M. Farrell Antidepressants for cocaine dependence Cochrane Database Syst Rev 2003 CD002950
76. S. Liu, M.J. Bubar, M.F. Lanfranco, G.R. Hillman, and K.A. Cunningham Serotonin2C receptor localization in GABA neurons of the rat medial prefrontal cortex: implications for understanding the neurobiology of addiction Neuroscience 146 2007 1677 1688
77. S. Liu, and K.A. Cunningham Serotonin2C receptors (5-HT2C R) control expression of cocaine-induced conditioned hyperactivity Drug Alcohol Depend 81 2006 275 282
78. G. Lucas, and U. Spampinato Role of striatal serotonin2A and serotonin2C receptor subtypes in the control of in vivo dopamine outflow in the rat striatum J Neurochem 74 2000 693 701
79. G.J. Madden, N.M. Petry, G.J. Badger, and W.K. Bickel Impulsive and self-control choices in opioid-dependent patients and non-drug-using control participants: drug and monetary rewards Exp Clin Psychopharmacol 5 1997 256 262
80. R. Mandrioli, G.C. Forti, and M.A. Raggi Fluoxetine metabolism and pharmacological interactions: the role of cytochrome p450 Curr Drug Metab 7 2006 127 133
81. S.M. McClure, D.I. Laibson, G. Loewenstein, and J.D. Cohen Separate neural systems value immediate and delayed monetary rewards Science 306 2004 503 507
82. J. McDaid, C.E. Tedford, A.R. Mackie, J.E. Dallimore, A.L. Mickiewicz, and F. Shen Nullifying drug-induced sensitization: behavioral and electrophysiological evaluations of dopaminergic and serotonergic ligands in methamphetamine-sensitized rats Drug Alcohol Depend 86 2007 55 66
83. C. McGregor, M. Srisurapanont, A. Mitchell, W. Wickes, and J.M. White Symptoms and sleep patterns during inpatient treatment of methamphetamine withdrawal: a comparison of mirtazapine and modafinil with treatment as usual J Subst Abuse Treat 35 2008 334 342
84. P. Mu, J.T. Moyer, M. Ishikawa, Y. Zhang, J. Panksepp, and B.A. Sorg Exposure to cocaine dynamically regulates the intrinsic membrane excitability of nucleus accumbens neurons J Neurosci 30 2010 3689 3699
85. K. Nakayama, T. Sakurai, and H. Katsu Mirtazapine increases dopamine release in prefrontal cortex by 5-HT1A receptor activation Brain Res Bull 63 2004 237 241
86. T.C. Napier, and E.D. Istre Methamphetamine-induced sensitization includes a functional upregulation of ventral pallidal 5-HT2A/2C receptors Synapse 62 2008 14 21
87. A. Nath Human immunodeficiency virus-associated neurocognitive disorder: pathophysiology in relation to drug addiction Ann N Y Acad Sci 1187 2010 122 128
88. S. Navailles, D. Moison, D. Ryczko, and U. Spampinato Region-dependent regulation of mesoaccumbens dopamine neurons in vivo by the constitutive activity of central serotonin2C receptors J Neurochem 99 2006 1311 1319
89. J.L. Neisewander, and J.I. Acosta Stimulation of 5-HT2C receptors attenuates cue and cocaine-primed reinstatement of cocaine-seeking behavior in rats Behav Pharmacol 18 2007 791 800
90. B.A. Nic Dhonnchadha, and K.A. Cunningham Serotonergic mechanisms in addiction-related memories Behav Brain Res 195 2008 39 53
91. B.A. Nic Dhonnchadha, R.G. Fox, S.J. Stutz, K.C. Rice, and K.A. Cunningham Blockade of the serotonin 5-ht2a receptor suppresses cue-evoked reinstatement of cocaine-seeking behavior in a rat self-administration model Behav Neurosci 123 2009 382 396
92. N. Nicosia, R.L. Pacula, B. Kilmer, R. Lundberg, and J. Chiesa The economic cost of methamphetamine use in the United States, 2005 2009 CA Rand Corporation Santa Monica
93. A.A. Nierenberg Do some antidepressants work faster than others? J Clin Psychiatry 62 Suppl. 15 2001 22 25
94. C.M. Niswender, K. Herrick-Davis, G.E. Dilley, H.Y. Meltzer, J.C. Overholser, and C.A. Stockmeier RNA editing of the human serotonin 5-HT2C receptor. alterations in suicide and implications for serotonergic pharmacotherapy Neuropsychopharmacology 24 2001 478 491
95. C.M. Niswender, E. Sanders-Bush, and R.B. Emeson Identification and characterization of RNA editing events within the 5-HT2C receptor Ann N Y Acad Sci 861 1998 38 48
96. C.P. O'Brien, A.R. Childress, R. Ehrman, and S.J. Robbins Conditioning factors in drug abuse: can they explain compulsion? J Psychopharmacol 12 1998 15 22
97. C.P. O'Brien, and E.L. Gardner Critical assessment of how to study addiction and its treatment: human and non-human animal models Pharmacol Ther 108 2005 18 58
98. G.N. Pandey, Y. Dwivedi, X. Ren, H.S. Rizavi, G. Faludi, and A. Sarosi Regional distribution and relative abundance of serotonin(2c) receptors in human brain: effect of suicide Neurochem Res 31 2006 167 176
99. N.S. Pentkowski, F.D. Duke, S.M. Weber, L.A. Pockros, A.P. Teer, and E.C. Hamilton Stimulation of medial prefrontal cortex serotonin 2C (5-HT(2C)) receptors attenuates cocaine-seeking behavior Neuropsychopharmacology 35 2010 2037 2048
100. M.E. Rose, and J.E. Grant Pharmacotherapy for methamphetamine dependence: a review of the pathophysiology of methamphetamine addiction and the theoretical basis and efficacy of pharmacotherapeutic interventions Ann Clin Psychiatry 20 2008 145 155
101. M. Sala, F. Coppa, C. Cappucciati, P. Brambilla, G. d'Allio, and E. Caverzasi Antidepressants: their effects on cardiac channels, QT prolongation and Torsade de Pointes Curr Opin Investig Drugs 7 2006 256 263
102. SAMHSA Drug Abuse Warning Network, 2006: National Estimates of Drug-Related Emergency Department Visits DAWN DAWN Series D-30, DHHS Publication No. (SMA) 08-4339, Rockville, MD 2008
103. N.L. Schramm-Sapyta, C.M. Olsen, and D.G. Winder Cocaine self-administration reduces excitatory responses in the mouse nucleus accumbens shell Neuropsychopharmacology 31 2006 1444 1451
104. J. Serrats, G. Mengod, and R. Cortes Expression of serotonin 5-HT2C receptors in GABAergic cells of the anterior raphe nuclei J Chem Neuroanat 29 2005 83 91
105. B. Setlow, I.A. Mendez, M.R. Mitchell, and N.W. Simon Effects of chronic administration of drugs of abuse on impulsive choice (delay discounting) in animal models Behav Pharmacol 20 2009 380 389
106. M.S. Sodhi, P.W. Burnet, A.J. Makoff, R.W. Kerwin, and P.J. Harrison RNA editing of the 5-HT(2C) receptor is reduced in schizophrenia Mol Psychiatry 6 2001 373 379
107. E. Spina, V. Santoro, and C. D'Arrigo Clinically relevant pharmacokinetic drug interactions with second-generation antidepressants: an update Clin Ther 30 2008 1206 1227
108. S.M. Stahl, M.M. Grady, C. Moret, and M. Briley SNRIs: their pharmacology, clinical efficacy, and tolerability in comparison with other classes of antidepressants CNS Spectr 10 2005 732 747
109. M.L. Stitzer, and R. Vandrey Contingency management: utility in the treatment of drug abuse disorders Clin Pharmacol Ther 83 2008 644 647
110. E. Stormer, L.L. von Moltke, R.I. Shader, and D.J. Greenblatt Metabolism of the antidepressant mirtazapine in vitro: contribution of cytochromes P-450 1A2, 2D6, and 3A4 Drug Metab Dispos 28 2000 1168 1175
111. H.K. Thanacoody, and S.H. Thomas Tricyclic antidepressant poisoning: cardiovascular toxicity Toxicol Rev 24 2005 205 214
112. C.J. Timmer, J.M. Sitsen, and L.P. Delbressine Clinical pharmacokinetics of mirtazapine Clin Pharmacokinet 38 2000 461 474
113. T.M. Tzschentke Measuring reward with the conditioned place preference paradigm: a comprehensive review of drug effects, recent progress and new issues Prog Neurobiol 56 1998 613 672
114. L. Urichuk, T.I. Prior, S. Dursun, and G. Baker Metabolism of atypical antipsychotics: involvement of cytochrome p450 enzymes and relevance for drug-drug interactions Curr Drug Metab 9 2008 410 418
115. F. Vocci, and W. Ling Medications development: Successes and challenges Pharmacol Ther 108 2005 94 108
116. R.M. Voigt, A.L. Mickiewicz, and T.C. Napier Repeated mirtazapine nullifies the maintenance of previously established methamphetamine-induced conditioned place preference in rats Behav Brain Res 225 2011 91 96
117. R.M. Voigt, and T.C. Napier Context-dependent effects of a single administration of mirtazapine on the expression of methamphetamine-induced conditioned place preference Front Behav Neurosci 5 2011 92
118. N.D. Volkow, G.J. Wang, Y. Ma, J.S. Fowler, W. Zhu, and L. Maynard Expectation enhances the regional brain metabolic and the reinforcing effects of stimulants in cocaine abusers J Neurosci 23 2003 11461 11468
119. N.D. Volkow, G.J. Wang, F. Telang, J.S. Fowler, J. Logan, and A.R. Childress Cocaine cues and dopamine in dorsal striatum: mechanism of craving in cocaine addiction J Neurosci 26 2006 6583 6588
120. N.D. Volkow, G.J. Wang, F. Telang, J.S. Fowler, J. Logan, and A.R. Childress Dopamine increases in striatum do not elicit craving in cocaine abusers unless they are coupled with cocaine cues Neuroimage 39 2008 1266 1273
121. Q. Wang, P.J. O'Brien, C.X. Chen, D.S. Cho, J.M. Murray, and K. Nishikura Altered G protein-coupling functions of RNA editing isoform and splicing variant serotonin2C receptors J Neurochem 74 2000 1290 1300
122. T.D. Werry, R. Loiacono, P.M. Sexton, and A. Christopoulos RNA editing of the serotonin 5HT2C receptor and its effects on cell signalling, pharmacology and brain function Pharmacol Ther 119 2008 7 23
123. H.G. Westenberg Pharmacology of antidepressants: selectivity or multiplicity? J Clin Psychiatry 60 Suppl. 17 1999 4 8
124. S.J. Yoon, C.U. Pae, D.J. Kim, K. Namkoong, E. Lee, and D.Y. Oh Mirtazapine for patients with alcohol dependence and comorbid depressive disorders: a multicentre, open label study Prog Neuropsychopharmacol Biol Psychiatry 30 2006 1196 1201
125. M. Yucel, and D.I. Lubman Neurocognitive and neuroimaging evidence of behavioural dysregulation in human drug addiction: implications for diagnosis, treatment and prevention Drug Alcohol Rev 26 2007 33 39
126. G.J. Yuen, D.M. Morris, P.K. Mydlow, S. Haidar, S.T. Hall, and E.K. Hussey Pharmacokinetics, absolute bioavailability, and absorption characteristics of lamivudine J Clin Pharmacol 35 1995 1174 1180
127. G.J. Yuen, S. Weller, and G.E. Pakes A review of the pharmacokinetics of abacavir Clin Pharmacokinet 47 2008 351 371
128. X.F. Zhang, X.T. Hu, and F.J. White Whole-cell plasticity in cocaine withdrawal: reduced sodium currents in nucleus accumbens neurons J Neurosci 18 1998 488 498